Results 101 to 110 of about 1,436,522 (338)

PD‐1 Inhibits CD4+ TRM‐Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC

open access: yesAdvanced Science, EarlyView.
CD4+ tissue‐resident memory T cells (TRMs) in non‐small cell lung cancer recruit conventional type 1 dendritic cells via XCL1‐XCR1 signaling, orchestrating antitumor immunity. The costimulatory molecule JAML is essential for this process. PD‐1 blockade restores JAML expression and cDC1 mobilization, while JAML agonists synergize with anti‐PD‐1 therapy,
Zheyu Shao   +16 more
wiley   +1 more source

Deep Multi-instance Networks with Sparse Label Assignment for Whole Mammogram Classification

open access: yes, 2017
Mammogram classification is directly related to computer-aided diagnosis of breast cancer. Traditional methods rely on regions of interest (ROIs) which require great efforts to annotate.
C Varela   +8 more
core   +1 more source

Preliminary 3-Year Evaluation of Experience With SilkSurface and VelvetSurface Motiva Silicone Breast Implants: A Single-Center Experience With 5813 Consecutive Breast Augmentation Cases

open access: yesAesthetic surgery journal, 2017
Background Silicone breast implants have been in use for breast augmentation for more than 50 years, but technological innovation has been lacking in implant design until recently.
M. Sforza   +8 more
semanticscholar   +1 more source

Regulating Tumor Metabolic Reprogramming with Biomimetic Co‐Delivery of Simvastatin and Kynureninase for Immunotherapy

open access: yesAdvanced Science, EarlyView.
After the intravenous injection of biomimetic and pH/ROS‐responsive PTSK@CRM, the nanoparticles can be accumulated in tumors and release Sim and KYNase to inhibit the tumor growth, regulate the metabolism of cholesterol and Kyn, and reverse the immunosuppressive tumor microenvironment.
Jiaxin Yin   +6 more
wiley   +1 more source

Metformin Impairs Breast Cancer Growth through the Inhibition of PRMT6

open access: yesAdvanced Science, EarlyView.
Metformin has a biological activity against breast cancer. However, it is largely unknown about its precise therapeutic targets. Here, histone arginine methyltransferase PRMT6 is identified as a new anti‐cancer target for metformin. Metformin directly binds PRMT6 and inhibits its ability to catalyze histone H3R2 asymmetric dimethylation (H3R2me2a ...
Yinsheng Wu   +9 more
wiley   +1 more source

Secondary Implant Augmentation in the Subpectoral Plane following Abdominal-based Perforator Flaps for Breast Reconstruction

open access: yesPlastic and Reconstructive Surgery, Global Open, 2020
Background:. Abdominal-based perforator flaps are the gold standard for autologous breast reconstruction. However, among patients with a small-to-medium amount of redundant abdominal tissue, this may result in an inadequate breast mound.
Muayyad Alhefzi, MBBS   +4 more
doaj   +1 more source

Focal Spot, Spring 1995 [PDF]

open access: yes, 1995
https://digitalcommons.wustl.edu/focal_spot_archives/1069/thumbnail ...

core   +1 more source

Cancer Cell‐Intrinsic Cholesterol Induces Lipid‐Associated Macrophage Differentiation via SP1 Palmitoylation to Promote Prostate Cancer Progression

open access: yesAdvanced Science, EarlyView.
Cancer cell‐intrinsic cholesterol promotes the S‐palmitoylation of SP1, increasing its nuclear translocation and driving the transcription and secretion of MDK, which in turn facilitates the differentiation of macrophages into a lipid‐associated phenotype.
Shirong Peng   +12 more
wiley   +1 more source

Six-Year Prospective Outcomes of Primary Breast Augmentation With Nano Surface Implants

open access: yesAesthetic surgery journal, 2018
Background Motiva Implants (Establishment Labs Holdings Inc.) are a novel family of silicone breast implants using cutting-edge technologies engineered to optimize aesthetic and safety outcomes. Objectives The authors sought to prospectively evaluate the
Manuel Chacón Quirós   +2 more
semanticscholar   +1 more source

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

open access: yesAdvanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun   +23 more
wiley   +1 more source

Home - About - Disclaimer - Privacy